Focusing on quality patient care in the new global subsidy for malaria medicines.
Tido von Schoen-Angerer and colleagues discuss the new Affordable Medicines Facility for malaria (AMFm), which subsidizes and facilitates access to artemisinin-based combination therapy, and what mechanisms are needed to ensure it stays focused on quality patient care.
Moon
Suerie
S
Giorgio Ruffolo Doctoral Research Fellow, Sustainability Science Program, Center for International Development, Kennedy School of Government, Harvard University, Cambridge, Massachusetts, USA.
Pérez Casas
Carmen
C
Kindermans
Jean-Marie
JM
de Smet
Martin
M
von Schoen-Angerer
Tido
T
D000962:Antimalarials / Q000191:economics* / Q000600:supply & distribution / Q000627:therapeutic use; D037621:Artemisinins / Q000191:economics* / Q000600:supply & distribution / Q000627:therapeutic use; D003695:Delivery of Health Care / Q000191:economics / Q000592:standards*; D004359:Drug Therapy, Combination; D005381:Financing, Organized; D014943:Global Health; D006297:Health Services Accessibility / Q000191:economics; D006801:Humans; D007391:International Cooperation; D016778:Malaria, Falciparum / Q000188:drug therapy* / Q000191:economics; D011787:Quality of Health Care
D000962:Antimalarials; D037621:Artemisinins; C031327:artemisinin